About Chitosan
Chitosan is a deacetylated chitin fiber from the shells of shrimp, crab, and other crustaceans, marketed as a 'fat blocker' for weight loss and cholesterol via binding dietary fat and bile acids in the gut. The clinical reality is modest: the Cochrane systematic review found the apparent ~1.7 kg weight-loss benefit collapses to a non-significant ~0.6 kg once restricted to high-quality trials. Cholesterol meta-analyses show statistically significant but clinically negligible reductions in total and LDL cholesterol. EFSA granted an authorized cholesterol-maintenance claim at 3 g/day, reflecting a consistent small effect rather than a strong one. LipoSan Ultra is a branded faster-absorbing form. Shellfish-derived — avoid with shellfish allergy; mild GI side effects (notably constipation) are common. No established RDA or UL.
What Chitosan supports
- Small short-term weight loss in pooled trials (~1.7 kg) that shrinks to clinically insignificant in high-quality studies
- Statistically significant but small reductions in total and LDL cholesterol (~3 g/day; EFSA-authorized claim)
- Shellfish-derived fat-binding fiber — avoid if allergic to shellfish
How much Chitosan to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
1500–3000
mg
RCT doses ranged 0.34-3.4 g/day (mean ~2 g/day), commonly ~3 g/day with meals; EFSA set its LDL-cholesterol claim at 3 g/day. Range 1.5-3 g/day brackets the higher-quality trials and the branded fast-absorbing LipoSan Ultra.
Clinical evidence
Limited clinical evidence. Cochrane review (15 RCTs): the ~1.7 kg weight loss shrinks to a non-significant ~0.6 kg in high-quality trials ('unlikely to be of clinical significance'); lipid meta-analyses show small, clinically negligible cholesterol reductions; EFSA's 3 g/day claim is regulatory, not a large clinical effect
Examine.com